Clinical trials: Glaucoma, Open-Angle Glaucoma Eye
Glaucoma
Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma
Prospective, multicenter, single-arm study of the iStent infinite in adult pseudophakic or phakic subjects with mild to moderate primary open angle glaucoma who have not failed conventional medical and surgical treatment
- Trial name
- NCT06057051
- Testing
- iStent Infinite
- Where
- United States
- Volunteers
- 245 people
- Sponsor
- Glaukos Corporation
Open-Angle Glaucoma, Ocular Hypertension
A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS)
The study objective is to compare IOP and safety outcomes based on plug placement (upper or lower puncta).
- Trial name
- NCT00821002
- Testing
- Latanoprost
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Mati Therapeutics Inc.
Glaucoma, Open-Angle
Early Evaluation of the Beacon Aqueous Microshunt in Patients Refractory to Drug Therapy in the European Union
This is prospective, non-randomized, single-arm study to assess the safety and effectiveness of lowering intraocular pressure with the Beacon Aqueous Microshunt. A total of 65 subjects will be enrolled at five centers.
- Trial name
- EARLY BIRD EU (NCT03634319)
- Testing
- Beacon Aqueous Microshunt
- Where
- 2 sites in Germany
- Volunteers
- 10 people
- Sponsor
- MicroOptx
Open Angle Glaucoma, Ocular Hypertension
A Study to Investigate the Effect of IOP-lowering With TO-O-1001 Eye Drops in Healthy Subjects and in Patients With Open-Angle Glaucoma or Ocular Hypertension
This is a Phase I/II stage to investigate the safety, tolerability, and ocular hypotensive efficacy of TO-O-1001 in healthy volunteers and patients with Open-Angle Glaucoma or Ocular Hypertension.
- Trial name
- NCT05456724
- Testing
- TO-O-1001
- Where
- Australia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Theratocular Biotek Co.
Primary Open-Angle Glaucoma, Optic Nerve Injury
A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy
This is a randomized, double-masked, placebo-controlled Phase II clinical trial. The primary objective is to explore the efficacy of G01 Eye Drops in the treatment of optic nerve injury associated with open-angle glaucoma…
- Trial name
- NCT07777861
- Testing
- G01 Eye Drops 100μg/ml, G01 Eye Drops 200μg/ml
- Where
- 9 sites in China
- Volunteers
- 90 people
- Sponsor
- Qingdao WanMing BioCell Pharmaceutics Co.,Ltd.
Glaucoma, Open-Angle, Ocular Hypertension
A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)
This study will evaluate the safety and efficacy of bimatoprost 0.01% in subjects with elevated intraocular pressure (IOP) due to primary open-angle glaucoma (POAG) or ocular hypertension (OH).
- Trial name
- NCT01594970
- Testing
- Bimatoprost 0.01%
- Where
- South Korea
- Volunteers
- 800 people
- Sponsor
- Allergan
Glaucoma, Open-angle, Ocular Hypertension (OHT)
Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone
This trial will evaluate the safety and IOP -lowering efficacy of administering an iDose TR (travoprost intracameral implant) in conjunction with cataract surgery compared to cataract surgery alone
- Conditions
- Glaucoma, Open-angle, Ocular Hypertension (OHT), Phacoemulsification Cataract Surgery
- Trial name
- NCT06848946
- Testing
- iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Glaukos Corporation
Ocular Hypertension, Open-Angle Glaucoma
A Three Part Study of MGV354 in Ocular Hypertension or Glaucoma
The purpose of this study is to determine if the clinical profile of topical-ocular MGV354 merits further development for the indication of lowering intraocular pressure (IOP).
- Trial name
- NCT02743780
- Testing
- MGV354 ophthalmic suspension
- Volunteers
- 191 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Primary Open-angle Glaucoma
PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)
Objectives: To evaluate the non-inferiority in the intraocular pressure decrease of the preservative-free ophthalmic solution PRO-122, manufactured by Laboratorios Sophia S.A.
- Trial name
- PRO-122LATAM (NCT03193333)
- Testing
- PRO-122, Timolol eye drops, Dorzolamide-Timolol Ophthalmic
- Where
- 2 sites in Colombia, Mexico
- Volunteers
- 51 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Open-angle Glaucoma, Ocular Hypertension
Travacom Post Marketing Surveillance Study
The purpose of this multi-center, open label, single arm, post-marketing surveillance study is to assess the safety of Travacom in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to…
- Trial name
- NCT01510132
- Testing
- Travoprost/timolol fixed combination (Travacom)
- Sponsor
- Alcon Research
Open-Angle Glaucoma, Ocular Hypertension
A Phase III Study of Travoprost/Timolol Combination in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to demonstrate equivalent safety and IOP-lowering effectiveness of two Travoprost/Timolol combination products in patients diagnosed with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00672997
- Testing
- Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution, Travoprost 0.004%/Timolol 0.5% ophthalmic solution
- Volunteers
- 301 people
- Sponsor
- Alcon Research
Ocular Hypertension, Open-angle Glaucoma
Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies
The purpose of this study is to compare the efficacy and safety of the preservative-free fixed tafluprost-timolol combination to those of tafluprost and timolol alone.
- Trial name
- NCT01292460
- Where
- 2 sites in Finland
- Volunteers
- 600 people
- Sponsor
- Santen Oy
Primary Open Angle Glaucoma, Ocular Hypertension
Study of LL-BMT1 in Patients With Elevated Intraocular Pressure
This is an open-label, Phase 2a clinical study of LL-BMT1 in patients with primary open-angle glaucoma and ocular hypertension. Study subjects will be treated for 7 days with a single dose of LL-BMT1.
- Trial name
- NCT04747808
- Testing
- LL-BMT1
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- MediPrint Ophthalmics, Inc.
Open Angle Glaucoma, Ocular Hypertension
Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues
This study will evaluate hyperemia and ocular surface tolerability in patients on prostaglandin analogues
- Trial name
- NCT00539526
- Testing
- Bimatoprost 0.03%, travoprost 0.004%, latanoprost 0.005% eye drops
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Allergan
Primary Open-Angle Glaucoma (POAG)
GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma
This is an investigator initiated, single center, open label, non-randomized, exploratory clinical study. The purpose is to assess the safety and preliminary efficacy of gene therapy GVB-2001 (ScAAV2-dnRhoA) delivered via…
- Trial name
- NCT06921317
- Testing
- GVB-2001-high dose, GVB-2001-low dose
- Where
- China
- Volunteers
- 6 people
- Sponsor
- IVIEW Therapeutics Inc.
Glaucoma, Primary Open Angle, Ocular Hypertension
A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons
The study will evaluate patients diagnosed with primary open angle glaucoma or ocular hypertension who are switched to Lumigan® UD monotherapy for medical reasons in accordance with physician standard clinical practice.
- Trial name
- NCT01853085
- Testing
- Bimatoprost Ophthalmic Solution
- Where
- Germany
- Volunteers
- 1,830 people
- Sponsor
- Allergan